MedCap AB (publ) (MCAP) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.034x

Based on the latest financial reports, MedCap AB (publ) (MCAP) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr51.70 Million ≈ $5.56 Million USD) by net assets (Skr1.53 Billion ≈ $164.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MCAP net asset quality index to measure how much of total assets are equity-financed.

MedCap AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how MedCap AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MedCap AB (publ) earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

MedCap AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of MedCap AB (publ) ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Zhe Jiang Headman Machinery Co Ltd
SHG:688577
0.074x
Scandinavian Tobacco Group A/S
CO:STG
0.027x
Corticeira Amorim
LS:COR
0.036x
Jiangsu Gian Technology Co Ltd
SHE:300709
0.215x
Cleanaway Co Ltd
TW:8422
0.142x
Standard Lithium Ltd
NYSE MKT:SLI
-0.016x
Star Cement Limited
NSE:STARCEMENT
0.056x
Luoniushan Co Ltd
SHE:000735
0.012x

Annual Cash Flow Conversion Efficiency for MedCap AB (publ) (2007–2025)

The table below shows the annual cash flow conversion efficiency of MedCap AB (publ) from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see MedCap AB (publ) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr1.46 Billion
≈ $157.00 Million
Skr342.70 Million
≈ $36.88 Million
0.235x -15.94%
2024-12-31 Skr1.29 Billion
≈ $138.63 Million
Skr360.00 Million
≈ $38.74 Million
0.279x +25.89%
2023-12-31 Skr1.03 Billion
≈ $110.53 Million
Skr228.00 Million
≈ $24.54 Million
0.222x +122.94%
2022-12-31 Skr858.70 Million
≈ $92.41 Million
Skr85.50 Million
≈ $9.20 Million
0.100x -40.27%
2021-12-31 Skr697.70 Million
≈ $75.08 Million
Skr116.30 Million
≈ $12.52 Million
0.167x -13.19%
2020-12-31 Skr602.00 Million
≈ $64.78 Million
Skr115.60 Million
≈ $12.44 Million
0.192x -10.50%
2019-12-31 Skr332.80 Million
≈ $35.81 Million
Skr71.40 Million
≈ $7.68 Million
0.215x -35.16%
2018-12-31 Skr273.80 Million
≈ $29.47 Million
Skr90.60 Million
≈ $9.75 Million
0.331x +224.47%
2017-12-31 Skr267.70 Million
≈ $28.81 Million
Skr27.30 Million
≈ $2.94 Million
0.102x -63.41%
2016-12-31 Skr292.29 Million
≈ $31.45 Million
Skr81.46 Million
≈ $8.77 Million
0.279x +675.70%
2015-12-31 Skr308.15 Million
≈ $33.16 Million
Skr-14.92 Million
≈ $-1.61 Million
-0.048x -701.63%
2014-12-31 Skr280.63 Million
≈ $30.20 Million
Skr2.26 Million
≈ $243.00K
0.008x +106.43%
2013-12-31 Skr221.92 Million
≈ $23.88 Million
Skr865.00K
≈ $93.09K
0.004x -98.02%
2012-12-31 Skr195.48 Million
≈ $21.04 Million
Skr38.55 Million
≈ $4.15 Million
0.197x +16.49%
2011-12-31 Skr169.82 Million
≈ $18.28 Million
Skr28.75 Million
≈ $3.09 Million
0.169x -0.54%
2010-12-31 Skr179.99 Million
≈ $19.37 Million
Skr30.64 Million
≈ $3.30 Million
0.170x +67.04%
2009-12-31 Skr169.94 Million
≈ $18.29 Million
Skr17.32 Million
≈ $1.86 Million
0.102x +305.17%
2008-12-31 Skr134.11 Million
≈ $14.43 Million
Skr3.37 Million
≈ $362.99K
0.025x +49.35%
2007-12-31 Skr127.44 Million
≈ $13.71 Million
Skr2.15 Million
≈ $230.94K
0.017x --

About MedCap AB (publ)

ST:MCAP Sweden Medical Devices
Market Cap
$886.54 Million
Skr8.24 Billion SEK
Market Cap Rank
#9261 Global
#147 in Sweden
Share Price
Skr548.50
Change (1 day)
-0.54%
52-Week Range
Skr453.00 - Skr670.00
All Time High
Skr670.00
About

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more